130 related articles for article (PubMed ID: 38586029)
1. p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
Luo J; Chen Z; Qiao Y; Tien JC; Young E; Mannan R; Mahapatra S; He T; Eyunni S; Zhang Y; Zheng Y; Su F; Cao X; Wang R; Cheng Y; Seri R; George J; Shahine M; Miner SJ; Vaishampayan U; Wang M; Wang S; Parolia A; Chinnaiyan AM
bioRxiv; 2024 May; ():. PubMed ID: 38586029
[TBL] [Abstract][Full Text] [Related]
2. Acetylation of histone H2B marks active enhancers and predicts CBP/p300 target genes.
Narita T; Higashijima Y; Kilic S; Liebner T; Walter J; Choudhary C
Nat Genet; 2023 Apr; 55(4):679-692. PubMed ID: 37024579
[TBL] [Abstract][Full Text] [Related]
3. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
[TBL] [Abstract][Full Text] [Related]
4. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
Chen Z; Wang M; Wu D; Bai L; Xu T; Metwally H; Wang Y; McEachern D; Zhao L; Li R; Takyi-Williams J; Wang M; Wang L; Li Q; Wen B; Sun D; Wang S
J Med Chem; 2024 Apr; 67(7):5275-5304. PubMed ID: 38477974
[TBL] [Abstract][Full Text] [Related]
5. FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Caligiuri M; Williams GL; Castro J; Battalagine L; Wilker E; Yao L; Schiller S; Toms A; Li P; Pardo E; Graves B; Azofeifa J; Chicas A; Herbertz T; Lai M; Basken J; Wood KW; Xu Q; Guichard SM
Target Oncol; 2023 Mar; 18(2):269-285. PubMed ID: 36826464
[TBL] [Abstract][Full Text] [Related]
6. NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.
Parolia A; Eyunni S; Verma BK; Young E; Liu L; George J; Aras S; Das CK; Mannan R; Rasool RU; Luo J; Carson SE; Mitchell-Velasquez E; Liu Y; Xiao L; Gajjala PR; Jaber M; Wang X; He T; Qiao Y; Pang M; Zhang Y; Alhusayan M; Cao X; Tavana O; Hou C; Wang Z; Ding K; Chinnaiyan AM; Asangani IA
bioRxiv; 2024 Mar; ():. PubMed ID: 38464251
[TBL] [Abstract][Full Text] [Related]
7. CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers.
Waddell AR; Huang H; Liao D
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201346
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-4 activates androgen receptor through CBP/p300.
Lee SO; Chun JY; Nadiminty N; Lou W; Feng S; Gao AC
Prostate; 2009 Feb; 69(2):126-32. PubMed ID: 18819102
[TBL] [Abstract][Full Text] [Related]
9. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
Sardar S; McNair CM; Ravindranath L; Chand SN; Yuan W; Bogdan D; Welti J; Sharp A; Ryan NK; Schiewer MJ; DeArment EG; Janas T; Su XA; Butler LM; de Bono JS; Frese K; Brooks N; Pegg N; Knudsen KE; Shafi AA
bioRxiv; 2024 May; ():. PubMed ID: 38766099
[TBL] [Abstract][Full Text] [Related]
10. Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti J; Sharp A; Brooks N; Yuan W; McNair C; Chand SN; Pal A; Figueiredo I; Riisnaes R; Gurel B; Rekowski J; Bogdan D; West W; Young B; Raja M; Prosser A; Lane J; Thomson S; Worthington J; Onions S; Shannon J; Paoletta S; Brown R; Smyth D; Harbottle GW; Gil VS; Miranda S; Crespo M; Ferreira A; Pereira R; Tunariu N; Carreira S; Neeb AJ; Ning J; Swain A; Taddei D; ; Schiewer MJ; Knudsen KE; Pegg N; de Bono JS
Cancer Discov; 2021 May; 11(5):1118-1137. PubMed ID: 33431496
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.
Thomas JE; Wang M; Jiang W; Wang M; Wang L; Wen B; Sun D; Wang S
J Med Chem; 2023 Jun; 66(12):8178-8199. PubMed ID: 37276143
[TBL] [Abstract][Full Text] [Related]
13. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.
Chen Q; Yang B; Liu X; Zhang XD; Zhang L; Liu T
Theranostics; 2022; 12(11):4935-4948. PubMed ID: 35836809
[TBL] [Abstract][Full Text] [Related]
14. p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer.
Xu S; Fan L; Jeon HY; Zhang F; Cui X; Mickle MB; Peng G; Hussain A; Fazli L; Gleave ME; Dong X; Qi J
Cancer Res; 2020 Aug; 80(15):3074-3087. PubMed ID: 32522824
[TBL] [Abstract][Full Text] [Related]
15. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Vannam R; Sayilgan J; Ojeda S; Karakyriakou B; Hu E; Kreuzer J; Morris R; Herrera Lopez XI; Rai S; Haas W; Lawrence M; Ott CJ
Cell Chem Biol; 2021 Apr; 28(4):503-514.e12. PubMed ID: 33400925
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma.
Chang Q; Li J; Deng Y; Zhou R; Wang B; Wang Y; Zhang M; Huang X; Li Y
J Med Chem; 2024 Feb; 67(4):2466-2486. PubMed ID: 38316017
[TBL] [Abstract][Full Text] [Related]
17. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation.
Fu M; Wang C; Reutens AT; Wang J; Angeletti RH; Siconolfi-Baez L; Ogryzko V; Avantaggiati ML; Pestell RG
J Biol Chem; 2000 Jul; 275(27):20853-60. PubMed ID: 10779504
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer.
Waddell A; Mahmud I; Ding H; Huo Z; Liao D
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199844
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic mechanisms to propagate histone acetylation by p300/CBP.
Kikuchi M; Morita S; Wakamori M; Sato S; Uchikubo-Kamo T; Suzuki T; Dohmae N; Shirouzu M; Umehara T
Nat Commun; 2023 Jul; 14(1):4103. PubMed ID: 37460559
[TBL] [Abstract][Full Text] [Related]
20. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
